GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Modus Therapeutics Holding AB (OSTO:MODTX) » Definitions » Tariff Resilience Score

Modus Therapeutics Holding AB (OSTO:MODTX) Tariff Resilience Score : 0/10 (As of Jul. 08, 2025)


View and export this data going back to 2021. Start your Free Trial

What is Modus Therapeutics Holding AB Tariff Resilience Score?

Modus Therapeutics Holding AB has the Tariff Resilience Score of 0, which implies that the company might have .

Modus Therapeutics Holding AB has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Modus Therapeutics Holding AB might have .


Modus Therapeutics Holding AB  (OSTO:MODTX) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Modus Therapeutics Holding AB Tariff Resilience Score Related Terms

Thank you for viewing the detailed overview of Modus Therapeutics Holding AB's Tariff Resilience Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Modus Therapeutics Holding AB Business Description

Traded in Other Exchanges
Address
Olof Palmes gata 29 IV, Stockholm, SWE, 111 22
Modus Therapeutics Holding AB is a Swedish clinical biotechnology company developing a treatment for sepsis, endotoxemia, severe malaria, and other disorders with severe systemic inflammation, as well as states of anemia related to chronic inflammation, such as kidney diseases, through its patented polysaccharide, sevuparin. The drug candidate sevuparin has the opportunity to benefit patients and save large healthcare costs.

Modus Therapeutics Holding AB Headlines

No Headlines